Business
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n Highlights:\n National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture 20% share of Nigeria’s billion-dollar HIV/AIDS treatment market Lodonal to represent a significant “breakthrough” as the first affordable, non-toxic adjunct therapy for HIV/AIDSCompany expected to strengthen management team to spearhead commercialization throughout AfricaWith initial contracts expected shortly, company on-track to meet guidance of achieving profitability by end of current fiscal year ORLANDO, Fla., May 22, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing its novel patented, affordable, non-toxic therapy for the treatment of cancer, HIV, autoimmune disease, and other inflammatory conditions, today announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company’s breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity. The approval is for a one-day Immune System Regulator for the management of HIV/AIDS, which is based on the results of the Company’s 90-Day bridging trial in Nigeria that resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients.  Additionally, there was a reduction in opportunistic infections plus several Phase II multi-center, randomized studies that demonstrated improvements for patients treated with Lodonal when compared to placebo or standard of care. \"Receiving regulatory approval from one of Africa’s most stringent regulatory bodies is a resounding endorsement for Lodonal, Immune Therapeutics’ breakthrough therapy for patients with life-threatening diseases such as HIV/AIDS,” said Noreen Griffin, Chief Executive Officer of Immune Therapeutics, Inc.  “We thank our partners in Africa – our exclusive agent, GB Pharma Holdings and AHAR Pharma Limited – for working with Immune Therapeutics to achieve this critical and exciting milestone and look forward to their ...